


045636-5039



**IN THE UNITED STATES PATENT AND TRADEMARK
OFFICE**

IN RE APPLICATION OF:
THIBODEAU et al.

: GROUP ART UNIT: 1648

SERIAL NO: 09/632,806

FILED: 08/04/2000

: EXAMINER: Jeffrey S. PARKIN

FOR: USE OF HIV-1 gp120 AND gp160
PROTEINS MODIFIED IN THE V3 LOOP
FOR THE PREPARATION OF VACCINE
COMPOSITIONS AND FORMULATIONS
CONTAINING THE SAME

DECLARATION UNDER 37 C.F.R. 1.132

HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C.

SIR:

Now comes Professor Luc MONTAGNIER, who declares and states
that:

1. I am a graduate of PARIS UNIVERSITY
and received my M.D. degree in the year 1960.

2. I have been employed by INSTITUT PASTEUR for 28 years
as Chief of the Viral Oncology Unit in the
field of virology. being a full Professor since 1985

3. I am experienced in the field of virology and more specifically in
the field of retrovirus including HIV and vaccination against HIV as it emerges from
the publications list herewith attached.

4. I am a specialist of HIV and I have characterized HIV, as it emerges from US 4,708,818 for instance.

5. A composition which comprises:

- a recombinant HIV-1 envelope protein comprising a mutated V3 loop, wherein the mutated V3 loop comprises the GPGRAPH (SEQ ID NO:1) hexamer sequence flanked by the two basal cysteins but lacks all or a portion of the rest of the V3 loop, and at least

- a polyol or an ester or ether derivative thereof,

has unexpectedly the properties of inducing an immunity which is at the same time humoral, cellular, and mucosal with respect to divergent strains of HIV-1.

5. My understanding of Lavallée et al. is the following:

Lavallée et al. describe the expression and the characterization *in vitro*, of recombinant HIV-1 gp160 Env proteins in which the V3 loop is partially (envΔ3-GPGRAPH) or totally (envΔ3+) deleted.

The aim of said Article is to better understand the role of the V3 loop, which is immunodominant, hypervariable and corresponds to the principal neutralizing determinant in the immune response (page 984, left column).

These findings have led the Authors of said Article to formulate the following two hypothesis (page 984, right column):

- . the V3 loop could constitute a decoy for the immune system; the Authors of said Article consider that a modification in said loop could induce a neutralizing activity directed against other more conserved epitopes, which have a weak immunogenicity during natural infection *in vivo*;

- . they were also concerned with the role of the V3 loop in apoptosis.

To verify the first hypothesis, the Authors of said Article have prepared two recombinant gp160 Env proteins in which the V3 loop is either partially (envΔ3-GPGRAPH) or totally (envΔ3+) deleted, which could be useful in view to determine the potential of recombinant V3 loop modified proteins to induce broadly reactive neutralizing antibodies, i.e. able of neutralizing divergent HIV-1 isolates (see abstract and page 988, right column).

However, Lavallée et al. neither describes nor suggests the use of such modified glycoprotein in vaccinal compositions able to induce both an humoral

immunity (neutralizing antibodies, a cellular immunity (cytotoxic T-lymphocytes) and a mucosal immunity (production of secreting and neutralizing IgA) against HIV-1, and therefore does not suggest any particular pharmaceutically acceptable formulation.

Such properties are not obvious, considering the ordinary level of skill in the art, at the time of the invention, for whom the V3 loop is necessary for obtaining an immune response (T and B epitopes).

Consequently, when deleting the V3 loop with the aim of broadening the neutralizing spectra of antibodies to divergent HIV-1 isolates, it was not obvious to a person of ordinary skill in the art to induce an efficient immune response, i.e. humoral, cellular and mucosal, able to induce a large spectrum protection against different isolates of HIV-1.

It clearly emerges from the instant specification that recombinant proteins in which the V3 loop is partially or totally deleted effectively induce the three kinds of immunities, humoral, cellular and mucosal.

7. My understanding of Alving et al. is the following:

Alving et al. propose, to solve the problem of inducing an immune response, with any antigen, to use the transdermal route on intact skin (see column, 2, lines 17-23).

Moreover, Alving et al. clearly state that:

. topically applied formulations of antigen and liposomes did not induce an immune response equivalent to that induced by subcutaneous injection (see column 1, lines 60-67);

. it is recognized that "for previous vaccine applications using liposomes, the formulation was injected through the skin with a needles, as the majority of the licensed vaccines" (see column 8, lines 45-47).

Thus, the person of ordinary skill in the art at the time of the invention would not be motivated to select the mucosal route and to prepare an immunogenic composition formulated for administering directly to the mucous membrane and encompassing liposomal compositions comprising the specific antigen as specified above (recombinant gp120 or gp160) and a polyol or ester or ether derivative thereof, knowing that Lavallée et al. do not envisage applications of the

described recombinant gp160 and Alving et al. dissuade the person of ordinary skill in the art from using other administration routes than the subcutaneous one or the transdermal one.

Moreover, to my knowledge, Mannino et al. relate to immunogenic compositions comprising a non-immunogen peptide and at least a lipid, preferably phospholipids, sterols, spingolipids, glycolipids and other diacyl containing lipid structures (see column 7, lines 1-5).

Such a composition is able to induce selective antibody production against said non-immunogen peptide.

In this document, the nature of the peptide appears to be the factor determining the structure that results. That is those peptides that are hydrophilic or neutral appear to more often form vesicular structures whereas those that are amphipatic appear to more often form amorphous, particulate aggregate (see column 7, lines 34-40).

Moreover, even though in column 13, lines 50-52, it is specified that: "the dosage form can be oral, nasal, intramuscular, intravenous, intraperitoneal, intraocular, subcutaneous, intravaginal or on any mucosal surface", if we take in consideration the context of Mannino et al. (see column 13, lines 31-33 and examples), there is nowhere any indication of using effectively a mucosal administration to effectively solve the problem of HIV vaccination.

Indeed in Example 3, the only described dosage form is the intraperitoneal one.

The fact that there is no motivation for, or suggestion of, using effectively the mucosal route for HIV vaccination is supported by Alving et al., which, as specified hereabove, propose in view to solve the problem of inducing an immune response to any antigen to use the transdermal route on intact skin.


Therefore, contrary to the assertions of the Examiner, it would not have been obvious to a person having ordinary skill in the art at the time the invention was made to prepare a composition formulated for mucosal administration in view to induce an effective immune response knowing that:

- neither Mannino et al. nor Alving et al. suggest that mucosal route could be effective for HIV vaccination, and

- Lavallée et al. describe the expression and the characterization *in vitro*, of recombinant HIV-1 gp160 Env proteins in which the V3 loop is partially (envΔ3-GPGRAPH) or totally (envΔ3+) deleted.

8. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any Patent issued thereon.

January 10 2005
Date


(signature)

Luc MONTAGNIER
(Print or Type Name)

Pr. Luc Montagnier
President
World Foundation for AIDS Research and Prevention
1 rue Miollis, 75732 Paris Cedex 15 – France
Tel : (33-1) 1 45 68 45 99 – Fax (33-1) 1 42 73 37 45
E-mail: c.claircy-riviere@unesco.org

PROFESSIONAL PROFILE:

A world-renowned researcher who has devoted his life to contributing to solutions for medical problems of our times. Among his achievements is the isolation, with his French team, of the viruses causing AIDS (HIV1 and HIV2). Included in his research are seminal observations concerning the role of oxidative stress and infectious co-factors in the destruction of the immune system of infected patients. Besides his involvement in the design of new types of protective and therapeutic AIDS vaccines, his current studies are aimed at the diagnosis and treatment of similar microbial and viral factors associated with cancers, neuro-degenerative and auto-immune diseases. As a strong advocate of preventive medicine he is especially concerned with prolonging the active life of aging people. Beyond his scientific interest is his deep involvement with helping developing countries acquire knowledge of and access to modern medicine and preventive medicine. As President of the World Foundation for Aids Research and Prevention he has co-founded a center for the treatment, research and diagnosis of AIDS patients in the Ivory Coast, as well as supervising the creation of similar centers in other parts of Africa.

PROFESSIONAL BACKGROUND:

<u>Centre National de la Recherche Scientifique (C.N.R.S.)</u> Emeritus Research Director1999-Present
<u>Institute Pasteur</u> Emeritus Professor	2001-Present
<u>World Foundation for AIDS Research and Prevention</u> President	1993-Present
<u>Center for Molecular and Cellular Biology</u> <u>Queens College, New York</u> Distinguished Professor and Director	1997-2001
<u>Institute Pasteur</u> Head of the AIDS-Retrovirus Department	1991-1997
<u>Institute Pasteur</u> Professor	1985-2000
<u>Institute Pasteur</u> Director of the Virology Course	1980-1985
<u>Centre National de la Recherche Scientifique (C.N.R.S.)</u> Research Director	1974-1998

Institute Pasteur

Head of the Viral Oncology Unit 1972-2000

Institute du Radium, Orsay

Head of Laboratory 1965-1972

Centre National de la Recherche Scientifique (C.N.R.S.)

Research Associate 1967

Centre National de la Recherche Scientifique (C.N.R.S.)

Research Assistant 1963

Centre National de la Recherche Scientifique (C.N.R.S.)

Research Fellow 1960

Paris Faculte des Sciences

Assistant 1955-1960

SUMMARY OF ACCOMPLISHMENTS & AWARDS

- 2004 Inductee at the National Inventors Hall of Fame (USA)
- 2000 Prince of Asturias Award (Spain)
- 2000 Officer of the Mayo Order (Argentina)
- 1999 Institute of Health Sciences Prize (France)
- 1998 Warren Alpert Prize, (USA)
- 1997 Harry M. Rose, Lecturer in Infectious Diseases at Columbia University, New York (USA)
- 1997 German Red Cross Prize
- 1997 Japanese Red Cross Prize
- 1996 Rome "Fregene" Prize (Italy)
- 1995 Steve Chase Humanitarian Prize (USA)
- 1995 Neil Hamilton Fairley Prize (Royal College of Physicians, London)
- 1995 Hippocrates Prize (Hellenic Society for Internal Medicine, Greece)
- 1994 Atomic Energy Agency Prize (France)
- 1994 Amsterdam Foundation for Medicine Prize (Holland)
- 1994 Dutch Royal Academy of Sciences
- 1993 Commander of the Legion of Honor (France)
- 1993 King Faisal International Prize for Medicine (Saudi Arabia)
- 1990 Officer of the Legion of Honor (France)
- 1998 Japan Prize
- 1987 Gairdner Prize (Canada)
- 1986 Albert Lasker Prize (USA)
- 1986 Korber Foundation for European Research Prize (Germany)
- 1986 James Blundel Prize (UK)
- 1986 Louis Jeantet Prize (Switzerland)
- 1986 Commander of the National Order of Merit (France)
- 1985 Gallien Prize (France)

- 1984 Knight of the Legion of Honor (France)
- 1973 C.N.R.S. Silver Medal (France)
- 1971 Rozen Prize for Oncology (France)
- 1964 C.N.R.S. Bronze Medal (France)

EDUCATION

1960-1964 Postdoctoral Fellowships

- (1960-1963) Medical Research Council Virus Research Unit (Carshalton, UK)
- (1963-1964) Institute of Virology, (Glasgow, UK)
- 1960 University of Paris, Doctorate in Medicine
- 1955 University of Paris, B.S.
- 1953 University of Poitiers, Higher studies diploma in Natural Sciences

SIGNIFICANT MEMBERSHIPS

- 1996 Member of the French Academy of Sciences
- 1990 Corresponding Member of the Academie Francaise des Sciences
- 1990 Member of the European Molecular Biology Organization (EMBO)
- 1989 Member of the French Academy of Medicine
- 1987 Member of the Spanish Royal Academy of Sciences
- 1987 Corresponding Member of the Belgium Royal Academy of Medicine

DOCTOR HONORIS CAUSA OF THE FOLLOWING UNIVERSITIES AND COLLEGES: (1980-2000)

Universities of Louvain (Belgium), Salonique (Greece), Liege (Belgium), and Albert Einstein College of Medicine (USA), Universite Americaine de Paris (France), Universities of Bologna (Italy), Buenos Aires (Argentina), Urbino (Italy), Montreal (Quebec), London (UK) and Bucharest (Romania).

PUBLICATIONS

Books:

SIDA et VIH by L. Montagnier, I. Gluckman, and W. Rozenbaum. Flammarion Publisher, 1989 (In French, also in Italian).

New Concepts in AIDS Pathogenesis by L. Montagnier and M. L. Gougeon. M.Dekker Publisher, NY. 1993. (In English)

Des Virus et des Hommes by L. Montagnier. O. Jacob Publisher, Paris. 1994 (In French)

Oxydative Stress in AIDS, Cancer and Neurodegenerative Diseases by L. Montagnier, R. Olivier, and C. Pasquier. M.Dekker Publisher, NY. 1998 (In English)

Virus by L. Montagnier. Norton Publisher, NY. 2000 (In English)

Articles:

More than 350 papers have been published in peer-reviewed scientific journals including: Nature, Science, and Cell.

Available upon request

LANGUAGES

Fluent in French and English

PERSONAL

Born in Chabris , France

Married, 3 children

LIST OF PUBLICATIONS
of Luc Montagnier on AIDS

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

F. BARRE-SINOUSSE, J.C. CHERMANN, F. REY, M.T. NUGEYRE, S. CHAMARET, J. GRUEST, C. DAUGUET, C. AXLER-BLIN, F. VEZINET-BRUN, C. ROUZIOUX, W. ROZENBAUM & L. MONTAGNIER.

Science, 220, 868-871 (1983).

A new human T-lymphotropic retrovirus : characterization and possible role in lymphadenopathy and acquired immune deficiency syndromes.

L. MONTAGNIER, J.C. CHERMANN, F. BARRE-SINOUSSE, S. CHAMARET, J. GRUEST, M.T. NUGEYRE, F. REY, C. DAUGUET, C. AXLER-BLIN, F. VEZINET-BRUN, C. ROUZIOUX, G.A. SAIMOT, W. ROZENBAUM, J.C. GLUCKMAN, D. KLATZMANN, E. VILMER, C. GRISCELLI, C. FOYER-GAZENGEL & J.B. BRUNET.

In : *"Human T cell leukemia/lymphoma viruses"* (R.C. Gallo, M.E. Essex & L. Gross, eds.), Cold Spring Harbor Laboratory New-York, 363-379 (1984).

Sequences related to mouse mammary tumor virus genome in tumor cells and lymphocytes from patients with breast cancer.

M. CREPIN, R. LIDEREAU, J.C. CHERMANN, P. POUILLART, H. MAGAMENAT & L. MONTAGNIER.

Biochem. Biophys. Res. Commun., 118, n°1, 324-331 (1984).

A new type of retrovirus isolated from patients presenting with lymphadenopathy and acquired immune deficiency syndromes structural and antigenic relatedness with Equine Infectious Anemia Virus.

L. MONTAGNIER, C. DAUGUET, C. AXLER, S. CHAMARET, J. GRUEST, M.T. NUGEYRE, F. REY, F. BARRE-SINOUSSE & J.C. CHERMANN.

Ann. Virol. (Inst. Pasteur), 135E, 119-134 (1984).

Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

D. KLATZMANN, F. BARRE-SINOUSSE, M.T. NUGEYRE, C. DAUGUET, E. VILMER, C. GRISCELLI, F. BRUN-VEZINET, C. ROUZIOUX, J.C. GLUCKMAN, J.C. CHERMANN & L. MONTAGNIER.

Science, 225, 59-63 (1984).

Isolation of a new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS.

E. VILMER, C. ROUZIOUX, F. VEZINET-BRUN, A. FISCHER, J.C. CHERMANN, F. BARRE-SINOUSSE, C. GAZENGEL, C. DAUGUET, P. MANIGNE, C. GRISCELLI & L. MONTAGNIER.

The Lancet, 753-757 (1984).

Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or

lymphadenopathy syndrome.

F. BRUN-VEZINET, F. BARRE-SINOUSSE, A.G. SAIMOT, D. CHRISTOL, L. MONTAGNIER, C. ROUZIOUX, D. KLATZMANN, W. ROZENBAUM, J.C. GLUCKMAN & J.C. CHERMANN.
The Lancet, 1253-1256 (1984).

Prevalence of antibodies to lymphadenopathy-associated retrovirus in african patients with AIDS.

F. BRUN-VEZINET, C. ROUZIOUX, L. MONTAGNIER, S. CHAMARET, J. GRUEST, F. BARRE-SINOUSSE, D. GEROLDI, J.C. CHERMANN, J. McCORMICK, S. MITCHELL, P. PIOT, H. TAELEMAN, KAPITA BILA MIRLANGU, ODIO WOBIN, N. MBENDI, P. MAZEBO, KAYEMBE KALAMBAYI, C. BRIDTS, J. DESMYTER, F.M. FEINSOD & T.C. QUINN.
Science, 226, 453-456 (1984) .

Adaptation of Lymphadenopathy Associated Virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.

L. MONTAGNIER, J. GRUEST, S. CHAMARET, C. DAUGUET, C. AXLER, D. GUETARD, M.T. NUGEYRE, F. BARRE-SINOUSSE, J.C. CHERMANN, J.B. BRUNET, D. KLATZMANN & J.C. GLUCKMAN.
Science, 225, 63-66 (1984) .

Characterization of the RNA dependent DNA polymerase of a new human T lymphotropic retrovirus (lymphadenopathy associated virus).

M.A. REY, B. SPIRE, D. DORMONT, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN
Biochem. Biophys. Res. Commun., 121, N°1, 126-133 (1984).

Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome.

J.C. CHERMANN, F. BARRE-SINOUSSE, C. DAUGUET, F. BRUN-VEZINET, C. ROUZIOUX, W. ROZENBAUM & L. MONTAGNIER.
Antibiot. Chemother., 32, 48-53 (1984) .

Lymphadenopathy associated virus infection of a blood-donor recipient pair with acquired immunodeficiency syndrome.

P.M. FEORINO, V.S. KALYANARAMAN, H.W. HAVERKOS, C.D. CABRADILLA, D.T. WARFIELD, H.W. JAFFE, A.K. HARRISON, M.S. GOTTLIEB, D. GOLDFINGER, J.C. CHERMANN, F. BARRE-SINOUSSE, T.T. SPIRA, J.S. McDOUGAL, J.W. CURRAN, L. MONTAGNIER, F.A. MURPHY & D.P. FRANCIS.
Science, 225, 69-72 (1984).

Possible role of a new type of human T lymphotropic virus in the pathology of AIDS related syndromes.

L. MONTAGNIER, F. BARRE-SINOUSSE & J.C. CHERMANN.

In : "*Prog. Immunodef. Res. Therapy*" (C Griscelli and J. Vossen, eds.), 1984, 367-372.

A new human retrovirus associated with acquired immunodeficiency syndrome (AIDS) or AIDS-related symptoms.

F. BARRE-SINOUSSE, J.C. CHERMANN & L. MONTAGNIER.

In : *"Manipulation of host defense mechanisms"* (T. Aoki, E. Tsubura, I. Urushizaki), Excerpta Medica APCS N°38, 1983, 169-183.

Immune status of AIDS patients in France : Relationship with lymphadenopathy associated virus tropism.

D. KLATZMANN, M. CAVAILLE-COLL, J.B. BRUNET, W. ROZENBAUM, S. KERNBAUM, F. BARRE-SINOUSSE, J.C. CHERMANN, L. MONTAGNIER & J.C. GLUCKMAN.

Ann. New York Acad. Sci., 437, 228-237 (1984).

Characterization and possible role in AIDS of a new human T-lymphotropic retrovirus.

J.C. CHERMANN, F. BARRE-SINOUSSE & L. MONTAGNIER.

In : *"Acquired Immune Deficiency Syndrome"*, UCLA Symposia on Molecular and Cellular Biology, (Alan R. Liss, Inc. ed.) 16, 1984, 31-46.

Isolation of human T-lymphotropic retrovirus (LAV) from zairian married couple, one with AIDS, one with prodromes.

A. ELLRODT, PH. LE BRAS, L. PALAZZO, F. BRUN-VEZINET, P. SEGOND, L. MONTAGNIER, F. BARRE-SINOUSSE, M.T. NUGEYRE, F. REY, C. ROUZIOUX, R. CAQUET & J.C. CHERMANN.

The Lancet, 1383-1385 (23 Juin 1984).

Transmission experiments with human T-lymphotropic retroviruses and human AIDS tissue.

D.C. GAJDUSEK, H.L. AMYX, C.J. GIBBS Jr., D.M. ASHER, R.T. YANAGIHARA, P. RODGERS-JOHNSON, P.W. BROWN, P.S. SARIN, R.C. GALLO Jr., A. MALUISH, L.O. ARTHUR, R.V. GILDEN, L. MONTAGNIER, J.C. CHERMANN, F. BARRE-SINOUSSE, D. MILDVAN, U. MATHUR & R. LEAVITT.

The Lancet, 1415-1416 (23 Juin 1984).

High prevalence of lymphadenopathy virus (LAV) in european haemophiliacs.

M. MELBYE, R.J. BIGGAR, J.C. CHERMANN, L. MONTAGNIER, S. STENBJERG & R. EBBESEN.

The Lancet, 40-41 (7 Juillet 1984).

Antibodies to the core protein of Lymphadenopathy Associated Virus (LAV) in patients with AIDS.

V.S. KALYANARAMAN, C.D. CABRADILLA, J.P. GETCHELL, R. NARAYANAN, E.H. BRAFF, J.C. CHERMANN, F. BARRE-SINOUSSE, L. MONTAGNIER, T.J. SPIRA, J. KAPLAN, D. FISHBEIN, H.W. JAFFE, J.W. CURRAN & D.P. FRANCIS.

Science, 225, 321-323 (1984).

Role d'un nouveau type de retrovirus lymphotrope dans le SIDA.

L. MONTAGNIER, F. BARRE-SINOUSSE & J.C. CHERMANN.

Actualites hematologiques, 18eme Serie (Masson, ed.), 84-90 (1984).

Etat actuel des recherches virologiques sur le SIDA.

F. BARRE-SINOUSSE, J.C. CHERMANN & L. MONTAGNIER.

Syndrome Immunodeficitaire Acquis (Editions Douin), 15-22 (1984).

Retrovirus et syndrome d'immunodeficiency acquise (SIDA)

J.C. CHERMANN, F. BARRE et L. MONTAGNIER.

Bull. Acad. Nat. Med., 168, N°1, 288-295 (1984).

A new human retrovirus associated with acquired immunodeficiency syndrome (AIDS) or AIDS related complexes.

J.C. CHERMANN, F. BARRE-SINOUSSE & L. MONTAGNIER.

In : *"Infection, immunity and blood transfusion"* (R.Y Dodd, L.F. Barker, eds.), Progress in clinical and biological research, vol. 182, Alan R. Liss Inc., 329-342 (1985).

Lymphadenopathy associated virus in AIDS, lymphadenopathy associated syndrome, and classic kaposi patients in Greece.

G. PAPAEOANGELOU, J. ECONOMIDOU, J. KALLINIKOS, H. CHOREIMI, T. MANDALAKI, J. STRATIGOS, D. GEROLDI, F. BARRE-SINOUSSE, J.C. CHERMANN and L. MONTAGNIER.

The Lancet, 642 (1984).

Possible transmission of a human lymphotropic retrovirus (LAV) from mother to infant with AIDS.

E. YILMER, A. FISCHER, C. GRISCELLI, F. BARRE-SINOUSSE, V. VIE, J.C. CHERMANN, L. MONTAGNIER, C. ROUZIOUX, F. BRUN-VEZINET & W. ROZENBAUM.

The Lancet, 229-230 (1984).

Inactivation of lymphadenopathy associated virus by chemical disinfectants.

B. SPIRE, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN.

The Lancet, 899-901 (1984).

A novel human lymphotropic retrovirus (LAV) : new data on its biology and role in AIDS.

L. MONTAGNIER, F. BARRE-SINOUSSE, D. KLATZMANN, J.C. GLUCKMAN, C. ROUZIOUX, F. BRUN-VEZINET & J.C. CHERMANN.

Meeting on *"RNA Tumor Viruses in Human Cancer"*, Denver, U.S.A., Juin 1984.

Molecular cloning of lymphadenopathy-associated virus.

M. ALIZON, P. SONIGO, F. BARRE-SINOUSSE, J.C. CHERMANN, P. TIOLLAIS, L. MONTAGNIER & S. WAIN-HOBSON.

Nature, 312, 757-760 (1984).

AIDS priority.

L. MONTAGNIER.

Nature, 310, 446 (1984).

Intracellular location of the two small RNA coded by Epstein-Barr virus genome and their variations according to viral expression.

H. COLLANDRE, D. GUETARD & L. MONTAGNIER.

Ann. Virol. (Inst. Pasteur), 135E, 159-165 (1984).

Isolation of a new retrovirus from a patient at risk of AIDS.

L. MONTAGNIER (in coll. with F. BARRE-SINOUSSE, J.C. CHERMANN, F. REY, M.T. NUGEYRE, S. CHAMARET, J. GRUEST, C. DAUGUET, C. AXLER-BLIN, F. VEZINET-BRUN,

C. ROUZIOUX & W. ROZENBAUM.

In : "*AIDS opportunistic infections in hemophiliacs*" - Proceedings of the first german round-table discussion on AIDS and its implication in hemophiliacs (G. Landbeck, ed.), F.K. Schattauer Verlag, Stuttgart-New York, 19-24 (1984).

Inactivation of lymphadenopathy-associated virus by heat, gamma rays and ultraviolet light.

B. SPIRE, D. DORMONT, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN.

The Lancet, 188-189 (1985).

The possible role of a new lymphotropic retrovirus (LAV) in the pathogeny of AIDS and AIDS-related diseases.

F. BRUN-VEZINET, C. ROUZIOUX, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN.

Prog. Med. Virol., 32, 189-195 (1984).

Lymphadenopathy-associated viral antibody in AIDS.

J. LAURENCE, F. BRUN-VEZINET, S.E. SCHUTZER, C. ROUZIOUX, D. KLATZMANN, F. BARRE-SINOUSSE, J.C. CHERMANN & L. MONTAGNIER.

N. Engl. J. Med., 311, 1269-1273 (1984).

Experimental infection of chimpanzees with lymphadenopathy-associated virus.

H. McCLURE, B. SWENSON, F. KING, J.C. CHERMANN, F. BARRE-SINOUSSE, L. MONTAGNIER, J. EICHBERG, C. SAXINGER, R. GALLO, H. ALTER, H. MASUR, A. MACHER, C. LANE & A. FAUCI.

Jama, 252, N°8, 995 (1984).

Infection of chimpanzees with lymphadenopathy-associated virus.

D.P. FRANCIS, P.M. FEORINO, J.R. BRODERSON, H.M. McCLURE, J. P. GETCHELL, C. R. McGRATH, B. SWENSON, J.S. McDUGAL, E.L. PALMER, A.K. HARRISON, F. BARRE-SINOUSSE, J.C. CHERMANN, L. MONTAGNIER, J.W. CURRAN, C.D. CABRADILLA & V.S. KALYANARAMAN.

The Lancet, 1276-1277 (1984).

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

D. KLATZMANN, E. CHAMPAGNE, S. CHAMARET, J. GRUEST, D. GUETARD, T. HERCEND, J.C. GLUCKMAN & L. MONTAGNIER.

Nature, 312, 767-768 (1984).

Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus.

L. MONTAGNIER, F. CLAYEL, B. KRUST, S. CHAMARET, F. REY, F. BARRE-SINOUSSE & J.C. CHERMANN.

Virology, 144, 283-289 (1985).

Relationship of AIDS to other retroviruses.

S. WAIN-HOBSON, M. ALIZON & L. MONTAGNIER.

Nature, 313, 743 (1985).

Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome.

W. ROZENBAUM, D. DORMONT, B. SPIRE, E. VILMER, M. GENTILINI, C. GRISCELLI, L. MONTAGNIER, F. BARRE-SINOUSI & J.C. CHERMANN.

The Lancet, 450-451 (1985).

Lymphadenopathy syndrome in two thalassemic patients after LAV contamination by blood transfusion.

F. BOITEUX, E. VILMER, R. GIROT, J.Y. MULLER, C. ROUZIOUX, S. CHAMARET & L. MONTAGNIER.

New Engl. J. Med., 312, N°10, 648-649 (1985).

Viral Etiology of AIDS.

J.C. CHERMANN, F. BARRE-SINOUSI & L. MONTAGNIER.

In : *"Hormones and sexual factors in human cancer aetiology"* (J.P. Wolff, J.S. Scott, eds.), Elsevier Science Publishers B.V., 103-113 (1984).

Absence of antibodies to LAV in haemophiliacs treated with heat-treated factor VIII concentrate.

C. ROUZIOUX, S. CHAMARET, L. MONTAGNIER, V. CARNELLI, G. ROLLAND & P.M. MANNUCCI.

The Lancet, 271-272 (1985).

Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated french and belgian hemophiliacs.

C. ROUZIOUX, F. BRUN-VEZINET, A.M. COUROUCE, C. GAZENGEL, D. VERGOZ, J. DESMYTER, J. VERMYLEN, C. VERMYLEN, D. KLATZMANN, D. GEROLDI, C. BARREAU, F. BARRE-SINOUSI, J.C. CHERMANN, D. CHRISTOL & L. MONTAGNIER.

Ann. Int. Med., 102, 476-479 (1985).

Deficient LAV, neutralising capacity of sera from patients with AIDS or related syndromes.

F. CLAVEL, D. KLATZMANN & L. MONTAGNIER.

The Lancet, 879-880 (1985).

Inactivation du virus LAV (Lymphadenopathy-associated Virus) a l'aide d'agents chimiques ou physiques.

J.C. CHERMANN, B. SPIRE, F. BARRE-SINOUSI, D. DORMONT & L. MONTAGNIER.

La Nouvelle Gazette de la Transfusion, 35-36, 9 (1985).

Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS.

F. BARRE-SINOUSI, U. MATHUR-WAGH, F. REY, F. BRUN-VEZINET, S.R. YANCOVITZ, C. ROUZIOUX, L. MONTAGNIER, D. MILDVAN & J.C. CHERMANN.

JAMA, 253, N°12, 1737-1739 (1985).

Inhibition of RNA-dependent DNA polymerases of AIDS and SAIDS retroviruses by HPA-23 (Ammonium-21-tungsto-9-antimoniate).

D. DORMONT, B. SPIRE, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN.

Ann. Inst. Pasteur/Virol., 136E, 75-83 (1985).

Le SIDA et son virus.

L. MONTAGNIER, J.B. BRUNET & D. KLATZMANN.

La Recherche, 16, 750-760 (1985).

L'origine virale du SIDA : de la clinique à la biologie moléculaire.

D. KLATZMANN & L. MONTAGNIER.

Medecine/Sciences, 1, 141-146 (1985).

Lymphadenopathy Associated Virus (LAV) and AIDS.

L. MONTAGNIER & D. KLATZMANN.

Clinical Immunology Newsletter (1985).

L'étiologie virale du SIDA et son impact en Santé Publique.

L. MONTAGNIER.

JAMA, 10, N°99, 414-417 (1985).

Lymphadenopathy-AIDS virus : from molecular biology to pathogenicity.

L. MONTAGNIER.

Ann. Int. Med., 103, 689 (1985).

Lymphadenopathy associated virus and its etiological role in AIDS.

L. MONTAGNIER, J.C. CHERMANN, F. BARRE-SINOUSSE, D. KLATZMANN, S. WAIN-HOBSON, M. ALIZON, F. CLAVEL, F. BRUN-VEZINET, E. VILMER, C. ROUZIOUX, W. ROZENBAUM & J.C. GLUCKMAN.

In : *"Retroviruses in human lymphoma/leukemia"* (M. Miwa et al.eds.), Japan Sci. Soc. Press, Tokyo/VNU Science Press, Utrecht, 319-331 (1985).

Infection par le virus LAV (Lymphadenopathy/AIDS virus) et syndrome d'immunodéficit acquis.

J.C. GLUCKMAN, D. KLATZMANN & L. MONTAGNIER.

La Presse Médicale, 14, N°27, 1451-1453 (1985).

Données récentes sur le SIDA.

L. MONTAGNIER.

Le Concours Medical, 107, N°29, 2803-2806 (1985).

SIDA : acquisitions récentes.

L. MONTAGNIER.

Tempo Médical, N°205, 25-27 (1985).

Le SIDA et son origine virale.

L. MONTAGNIER.

Med. Malad. Infect., 5, 262 (1985).

Antibodies to LAV in various population groups of the Central African Republic.

A. GEORGES, J.L. LESBORDES, D.M.Y. MEUNIER, M.D. VOHITO, J.P. GONZALES, D. GUETARD, S. CHAMARET, G. BENSIMON, D. KLATZMANN & L. MONTAGNIER.

Ann. Virol. (Inst. Pasteur), 136E, n°4, 323-325 (1985).

Immunologic and virologic status of multitransfused patients : role of type and origin of blood products.

By the AIDS-Hemophilia French study group.

Blood, 66, N°4, 896-901 (1985).

Lymphadenopathy-associated virus : its role in the pathogeny of AIDS and related diseases.

L. MONTAGNIER.

Progress in Allergy, 37, 46-64 (1986).

The seroepidemiology of human AIDS.

L. MONTAGNIER.

In : *"Animals models of retrovirus infection and their relationship to AIDS"*, ed. Lois Ann Salzman, Academic Press, pp. 265-277 (1986).

Lymphadenopathy-associated-virus infection and acquired immunodeficiency syndrome.

J.C. GLUCKMAN & D. KLATZMANN.

Ann. Rev. Immunol., 4, 97-117 (1986).

Genetic structure of the Lymphadenopathy-AIDS virus.

S. WAIN-HOBSON & L. MONTAGNIER.

Cancer Rev., 1, 18-34 (1986).

Approaches to AIDS therapy.

D. KLATZMANN & L. MONTAGNIER.

Nature, 319, 10-11 (1986).

L'étiologie virale du SIDA.

F. CLAVEL et L. MONTAGNIER.

Revue du Praticien, 36, n°21, 1163-1167 (1986).

Screening for lymphadenopathy/AIDS virus in bone marrow transplant recipients.

E. VILMER, C. ROUZIOUX, F. BARRE-SINOSSI, J.C. CHERMANN, J.C. GLUCKMAN, A. DEVERGIE, L. MONTAGNIER & E. GLUCKMAN.

N. Engl. J. Med., 314, 1242 (1986).

LAV type II : un second retrovirus associé au SIDA en Afrique de l'Ouest.

F. CLAVEL, F. BRUN-VEZINET, D. GUETARD, S. CHAMARET, A. LAURENT, C. ROUZIOUX, M.A. REY, C. KATLAMA, F. REY, J.L. CHAMPALIMAUD, J.S. NINA, K. MANSINHO, M.O. SANTOS-FERREIRA, D. KLATZMANN & L. MONTAGNIER.

C.R. Acad. Sc. Paris, 302, Serie III, n°13, 485-488 (1986).

Isolation of a new human retrovirus from West African patients with AIDS.

F. CLAVEL, D. GUETARD, F. BRUN-VEZINET, S. CHAMARET, M.A. REY, M.O. SANTOS-FERREIRA, A.G. LAURENT, C. DAUGUET, C. KATLAMA, C. ROUZIOUX, D. KLATZMANN, J.L. CHAMPALIMAUD, L. MONTAGNIER.

Science, 233, 343-346 (1986) .

Dialogues therapeutiques - SIDA : Bientot un vaccin ?

L. MONTAGNIER.

Medecine et Hygiene, 44, 1026-1028 (1986).

Lymphadenopathy/AIDS virus : genetic organization and relationship to animal lentiviruses.

M. ALIZON & L. MONTAGNIER.

Anticancer Research, 6, 403-412 (1986) .

Genetic variability of the AIDS virus : nucleotide sequence analysis of two isolates from African patients.

M. ALIZON, S. WAIN-HOBSON, L. MONTAGNIER & P. SONIGO.

Cell, 46, 63-74 (1986).

Inhibition fonctionnelle par la ciclosporine A du recepteur lymphocytaire du virus du SIDA (HIV).

D. KLATZMANN, J.P. LAPORTE, A. ACHOUR, E. BRISSON, J. GRUEST, L. MONTAGNIER & J.C. GLUCKMAN. Presentation F. GROS.

C.R. Acad. Sci. Paris, 303, Serie III, n°9, 343-348 (1986).

AIDS virus env expressed from a recombinant vaccinia virus.

M.P. KIENY, G. RAUTMANN, D. SCHMITT, K. DOTT, S. WAIN-HOBSON, M. ALIZON, M. GIRARD, S. CHAMARET, A. LAURENT, L. MONTAGNIER & J.P. LECOCQ.

Biotechnology, 4, 790-795 (1986).

Transmissibility of human immunodeficiency virus in haemophilic and non-haemophilic children living in a private school in France.

A. BERTHIER, S. CHAMARET, R. FAUCHET, J. FONLUPT, N. GENETET, M. GUEGUEN, M. POMMEREUIL, A. RUFFAULT & L. MONTAGNIER.

The Lancet, 598-601 (13 Septembre 1986) .

Association of tyrosine protein kinase activity with mitochondria in human fibroblasts.

G. PIEDIMONTE, L. SILVOTTI, S. CHAMARET, A.F. BORGHETTI & L. MONTAGNIER.

J. of Cell. Biochem., 32, 113-123 (1986).

High production of the acquired immunodeficiency syndrome virus (Lymphadenopathy-associated virus) by human T lymphocytes stimulated by streptococcal mitogenic toxins.

J.E. ALOUF, C. GEOFFROY, D. KLATZMANN, J.C. GLUCKMAN, J. GRUEST & L. MONTAGNIER.

J. of Clin. Microbiol., 24, 639-641 (1986).

Molecular cloning and polymorphism of the human deficiency virus type 2.

F. CLAVEL, M. GUYADER, D. GUETARD, M. SALLE, L. MONTAGNIER & M. ALIZON.

Nature, 324, 691-695 (1986).

Transmission of Lymphadenopathy-Associated Virus/Human T lymphotropic virus type III in sexual partners.

H. BURGER, B. WEISER, W.S. ROBINSON, J. LIFSON, E. ENGLEMAN, C. ROUZIOUX, F. BRUN-VEZINET, F. BARRE-SINOUSSE, L. MONTAGNIER & J.C. CHERMANN.

Am. J. of Med., 81, 5-10 (1986).

A monoclonal antibody against LAV gag precursor : use for viral protein analysis and antigenic expression in infected cells.

J. CHASSAGNE, P. VERELLE, C. DIONET, F. CLAVEL, F. BARRE-SINOUSSE, J.C. CHERMANN, L. MONTAGNIER, J.C. GLUCKMAN & D. KLATZMANN.

J. Immunol., 136, 1442-1445 (1986).

Lymphadenopathy/AIDS virus : the prototype human lentivirus.

S. WAIN-HOBSON, P. SONIGO, M. ALIZON & L. MONTAGNIER. In : *"Modern Concepts and Therapeutic Challenges"* (S. Broder, ed.), Marcel Dekker, Inc., New York and Basel, pp. 23-37 (1987).

The AIDS virus : Structure and variation.

L. MONTAGNIER & S. WAIN-HOBSON. In : *"AIDS : The safety of blood and blood products"* (J.C. Petricciani, I.D. Gust, P.A. Hoppe & H.W. Krijnen, eds), by John Wiley & Sons Ltd., p. 1-10, 1987.

The human immune deficiency virus (HIV) : an update.

L. MONTAGNIER & M. ALIZON.

Ann. Inst. Pasteur/Virol., 138, 3-11 (1987).

AIDS subacute encephalitis : identification of HIV-infected cells.

R. VAZEUX, N. BROUSSE, A. JARRY, D. HENIN, C. MARCHE, C. VEDRENNE, J. MIKOL, M. WOLFF, C. MICHON, W. ROZENBAUM, J.F. BUREAU, L. MONTAGNIER & M. BRAHIC.

Am. J. of Path., 126, N°3, 403-410 (1987).

Genome organization and transactivation of the human immunodeficiency virus type 2.

M. GUYADER, M. EMERMAN, P. SONIGO, F. CLAVEL, L. MONTAGNIER & M. ALIZON.

Nature, 326, 662-669 (1987).

Human immunodeficiency virus type 2 infection associated with AIDS in West Africa.

F. CLAVEL, KAMAL MANSINHO, S. CHAMARET, D. GUETARD, V. FAVIER, J. NINA, M.O. SANTOS-FERREIRA, J.L. CHAMPALIMAUD & L. MONTAGNIER.

N. Engl. J. of Med., 316, N° 19, 1180-1185 (1987).

Detection of natural autoantibodies in the serum of anti-HIV-positive individuals.

P. MATSOTIA, S. CHAMARET, L. MONTAGNIER & S. AVRAMEAS.

Ann. Inst. Pasteur/Immunol., 138, 223-233 (1987).

A sensitive dot immunobinding assay for the detection of antibodies specific for HIV.

B. KRUST, A.G. LAURENT, L. MONTAGNIER & A.G. HOVANESSIAN.

Ann. Inst. Pasteur/Virol., 138, 245-252 (1987).

Les deux virus du SIDA.

L. MONTAGNIER.

Recherche et Santé, 31, 22-27 (1987).

WHO Working Group on characterization of HIV-related retroviruses : criteria for characterization and proposal for a nomenclature system.

G. BIBERFELD, F. BROWN, J. ESPARZA, M. ESSEX, R.C. GALLO, L. MONTAGNIER, R. NAJERA, R. RISSER & G. SCHILD.

AIDS, 1, 189-190 (1987).

HIV F/3'orf encodes a phosphorylated GTP-binding protein resembling an oncogene product.

B. GUY, M.P. KIENY, Y. RIVIERE, C. LE PEUCH, K. DOTT, M. GIRARD, L. MONTAGNIER & J.P. LECOCQ.

Nature, 330, 266-269 (1987).

Infection par le virus HIV-2 avec longue periode d'incubation.

N. BURIN des ROZIERES, A. BRUET, J.P. LEGER, C. COLLET, J.P. AUFEUVRE, J.P. FENDLER, S. CHAMARET & L. MONTAGNIER.

Presse Medicale, 16, N°39, 1981 (1987).

The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.

M. EMERMAN, M. GUYADER, L. MONTAGNIER, D. BALTIMORE & M.A. MUESING.

EMBO J., 6, N°12, 3755-3760 (1987).

Genetic variability in human immunodeficiency viruses.

M. ALIZON & L. MONTAGNIER.

Normal and neoplastic blood cells : from genes to therapy, *Annals of the New York Academy of Sciences*, 511, 376-384 (1987).

Anti HIV-2 serological screening in Portuguese populations native from or having had close contact with Africa.

F. SAAL, S. SIDIBE, E. ALVES-CARDOSO, A. TERRINHA, A. GESSAIN, Y. POIROT, L. MONTAGNIER & J. PERIES.

AIDS Research and Human Retroviruses, 3, N°4, 341-342 (1988).

Sequence analysis of the human immune deficiency virus type 2.

M. GUYADER, M. EMERMAN, P. SONIGO, F. CLAVEL, L. MONTAGNIER & M. ALIZON.

In : *"Human Retroviruses, Cancer and AIDS : Approaches to Prevention and Therapy"*, Alan R. Liss Inc., pp. 31-42 (1988).

Characterization of a monoclonal antibody specific for the HIV-1 precursor glycoprotein.

B. KRUST, A.G. LAURENT, A. LE GUERN, O. JEANNEQUIN, L. MONTAGNIER & A.G. HOVANESSIAN.

AIDS, 2, 17-24 (1988).

Concomitant infection by human herpes virus 6, HTLV-1, and HIV-2.

H. AGUT, D. GUETARD, H. COLLANDRE, C. DAUGUET, L. MONTAGNIER, J.M. MICLEA, H. BAURMANN & A. GESSAIN.

The Lancet, 712 (1988).

Enhancement of mitochondrial tyrosine kinase activity following viral transformation.

G. PIEDIMONTE, L. SILVOTTI, A.F. BORGHETTI & L. MONTAGNIER.

Cancer letters, 39, 1-8 (1988).

Identification and characterization of tyrosine kinase activity associated with mitochondrial outer membrane in sarcoma 180 cells.

G. PIEDIMONTE, S. CHAMARET, C. DAUGUET, A.G. BORGHETTI & L. MONTAGNIER.

J. of Cell Biochem., 36, 91-102 (1988).

HIV-2 antisera cross-neutralize HIV-1.

R.A. WEISS, P.R. CLAPHAM, J.N. WEBER, D. WHITBY, R.S. TEDDER, T. O CONNOR, S. CHAMARET & L. MONTAGNIER.

AIDS, 2, 95-100 (1988).

The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule.

Q.J. SATTENTAU, P.R. CLAPHAM, R.A. WEISS, P.C.L. BEVERLEY, L. MONTAGNIER, M.F. ALHALABI, J.C. GLUCKMAN & D. KLATZMANN.

AIDS, 2, 101-105 (1988).

Isotypic restriction of the antibody response to human immunodeficiency virus.

J. KHALIFE, B. GUY, M. CAPRON, M.P. KIENY, J.C. AMEISEN, L. MONTAGNIER, J.P. LECOCQ & A. CAPRON.

AIDS Research and Human Retroviruses, 4, N°1, 3-9 (1988).

Selective depletion of low density CD8+, CD16+ lymphocytes during HIV infection

F. VUILLIER, N.E. BIANCO, L. MONTAGNIER & G. DIGHERO.

AIDS Research and Human Retroviruses, 4, N°2, 121-129 (1988).

A molecular mechanism of inhibition of HIV-1 binding to CD4+ cells by monoclonal antibodies to gp120.

E. BAHRAOUI, B. CLERGET-RASLAIN, F. CHAPUIS, R. OLIVIER, C. PARAVICINI, M. YAGELLO, L. MONTAGNIER & J.C. GLUCKMAN

AIDS, 2, 165-169 (1988).

AIDS in 1988.

R.C. GALLO & L. MONTAGNIER.

Scientific American, 259, N°4, 40-48 (1988).

Origin and variations of immune deficiency viruses.

L. MONTAGNIER.

In : *"Human Retroviruses and diseases they cause"* (J.P. Allain, R.C. Gallo and L. Montagnier, eds.), Chicago, Illinois, p. 15-20 (1988).

Improved antigenicity of the HIV *env* protein by cleavage site removal.

M.P. KIENY, R. LATHE, Y. RIVIERE, K. DOTT, D. SCHMITT, M. GIRARD, L. MONTAGNIER & J.P. LECOCQ.

Protein Engineering, 2, N°3, 219-225 (1988).

HIV-2 in rhesus monkeys : serological, virological and clinical results.

D. DORMONT, J. LIVARTOWSKI, S. CHAMARET, D. GUETARD, D. HENIN, R. LEVAGUERESSE, P.F. VAN DE MOORTELE, B. LARKE, P. GOURMELON, R. VAZEUX, H. METIVIER, J. FLAGEAT, L. COURT, J.J. HAUW & L. MONTAGNIER.

Intervirolgy, 30, 59-65 (1988).

A rapid and simple colorimetric test for the study of anti-HIV agents.

O. SCHWARTZ, Y. HENIN, V. MARECHAL & L. MONTAGNIER.

AIDS Research and Human Retroviruses, 4, N°6, 441-448 (1988).

Adult T-cell leukemia associated with HTLV-1 and simultaneous infection by human immunodeficiency virus type 2 and human herpesvirus 6 in an african woman : a clinical, virologic, and familial serologic study.

H. BAURMANN, J.M. MICLEA, F. FERCHAL, A. GESSAIN, M.T. DANIEL, D. GUETARD, H. COLLANDRE, H. AGUT, S. CASTAIGNE, J.D. RAIN, L. MONTAGNIER, Y. PEROL, F. SIGAUX & L. DEGOS.

Am. J. of Med., 85, 853-857 (1988).

Efficiency of poly(A).poly(U) as an adjuvant.

A.G. HOVANESSIAN, J. GALABRU, Y. RIVIERE & L. MONTAGNIER.

Immunol. Today, 9, 161-162 (1988).

Functional analogies with cellular oncogene products imply a role for HIV-F (3 orf) in cell regulation.

B. GUY, M.P. KIENY, Y. RIVIERE, M. GIRARD, L. MONTAGNIER & J.P. LECOCQ.

In : *"Vaccines 88"*, Cold Spring Harbor Laboratory, New York, pp. 311-316 (1988).

Loss of CD4 membrane expression and CD4 mRNA during acute HIV replication.

P. SALMON, R. OLIVIER, Y. RIVIERE, E. BRISSON, J.C. GLUCKMAN, M.P. KIENY, L. MONTAGNIER & D. KLATZMANN.

J. Exp. Med., 168, 1953-1969 (1988).

Origin and evolution of HIVs and their role in AIDS pathogenesis.

L. MONTAGNIER.

J. of Acquired Immune Deficiency Syndromes, 1, 517-520 (1988).

Kinetics of lymphocyte proliferative responses to HIV-1 in vaccinated chimpanzees.

In : *"Retroviruses of human AIDS and related animal diseases"* (M. Girard, L. Valette, eds.), Fondation Merieux (Lyon), pp. 234-237 (1988).

Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus.
Y. RIVIERE, F. TANNEAU-SALVADORI, A. REGNAULT, O. LOPEZ, P. SANSONETTI, B. GUY, M.P. KIENY, J.J. FOURNEL & L. MONTAGNIER.
Res. Immunol., 140, 22-27 (1989).

Persistent antibody response to the HIV-1 negative regulatory factor in HIV-1 infected seronegative persons.
J.C. AMEISEN, B. GUY, J.P. LECOCQ, S. CHAMARET, L. MONTAGNIER, M. LOCHE, B. MACH, A. TARTAR, Y. MOUTON & A. CAPRON.
N. Engl. J. of Med., 320, N°4, 251-252 (1989).

Characterization of human immunodeficiency virus type 2 envelope glycoproteins : dimerization of the glycoprotein precursor during processing.
M.A. REY, B. KRUST, A.G. LAURENT, L. MONTAGNIER & A.G. HOVANESSIAN.
J. of Virol., 63, 647-658 (1989).

Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant Viruses.
J.P. VAN EENDENBURG, M. YAGELLO, M. GIRARD, M.P. KIENY, J.P. LECOCQ, E. MUCHMORE, P.N. FULTZ, Y. RIVIERE, L. MONTAGNIER & J.C. GLUCKMAN.
AIDS Research and Human Retroviruses, 5, N°1, 41-49 (1989).

VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes.
M. GUYADER, M. EMERMAN, L. MONTAGNIER & K. PEDEN.
EMBO J., 8, N°4, 1169-1175 (1989).

Antibodies to the *nef* protein and to *nef* peptides in HIV-1 infected seronegative individuals.
J.C. AMEISEN, B. GUY, S. CHAMARET, M. LOCHE, Y. MOUTON, J.L. NEYRINCK, J. KHALIFE, C. LEPREVOST, C. BEAUCAIRE, C. BOUTILLON, H. GRAS-MASSÉ, M. MANIEZ, M.P. KIENY, D. LAUSTRIAT, A. BERTHIER, B. MACH, L. MONTAGNIER, J.P. LECOCQ & A. CAPRON.
AIDS Research and Human Retroviruses, 5, N°3, 279-291 (1989).

Co-cultivation of human herpesvirus 6 and HIV-1 from blood lymphocytes.
H. AGUT, D. KEROUEDAN, P. MPELE, H. COLLANDRE, C. SAMBA-LEFEVRE, M. ROSENHEIM, D. INGRAND, A. ITOUA-NGAPORO, M. GENTILINI, L. MONTAGNIER & J.M. HURAUX.
Res. Virol. (Inst. Pasteur), 140, 23-26 (1989).

In vitro sensitivity of human herpesvirus-6 to antiviral drugs.
H. AGUT, H. COLLANDRE, J.T. AUBIN, D. GUETARD, V. FAVIER, D. INGRAND, L. MONTAGNIER & J.M. HURAUX.
Res. Virol. (Inst. Pasteur), 140, N°3, 219-228 (1989).

Les rétrovirus de l'immunodéficience chez l'homme et les primates.

L. MONTAGNIER

Bull. Acad. Natl. Med., 173, N°2, 185-191 (1989).

Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor.

E. FENOUILLET, B. CLERGET-RASLAIN, J.C. GLUCKMAN, D. GUETARD, L. MONTAGNIER & E. BAHRAOUI.

J. Exp. Med., 169, 807-822 (1989).

Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals : distinct types of effector cells mediate killing of targets expressing *gag* and *env* proteins.

Y. RIVIERE, F. TANNEAU-SALVADORI, A. REGNAULT, O. LOPEZ, P. SANSONETTI, B. GUY, M.P. KIENY, J.J. FOURNEL & L. MONTAGNIER.

J. of Virol., 63, N°5, 2270-2277 (1989).

Accessibility of the highly conserved amino- and carboxy-terminal regions from HIV-1 external envelope glycoproteins.

E. BAHRAOUI, B. CLERGET-RASLAIN, C. GRANIER, J. VAN RIETSCHOTEN, J.M. SABATIER, C. LABBE-JULIE, B. CEARD, H. ROCHAT, J.C. GLUCKMAN & L. MONTAGNIER.

AIDS Research and Human Retroviruses, 5, N°4, 451-463 (1989).

Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.

A. CORDONNIER, L. MONTAGNIER & M. EMERMAN.

Nature, 340, 571-574 (1989).

Cell surface expression of several species of human immunodeficiency virus type 1 major core protein.

A.G. LAURENT, B. KRUST, M.A. REY, L. MONTAGNIER & A.G. HOVANESSIAN.

J. of Virol., 63, N°9, 4074-4078 (1989).

Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding.

A. CORDONNIER, Y. RIVIERE, L. MONTAGNIER & M. EMERMAN.

J. of Virol., 63, N°10, 4464-4468 (1989).

Molecular analysis of receptor binding and infectivity of the human immunodeficiency virus.

A. CORDONNIER & L. MONTAGNIER

Res. Virol. (Inst. Pasteur), 140, 453-460 (1989).

Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein.

M.A. REY, B. KRUST, A.G. LAURENT, D. GUETARD, L. MONTAGNIER & A.G. HOVANESSIAN.

Virology, 173, 258-267 (1989).

Role des liposomes dans la présentation de la glycoprotéine de l'enveloppe du VIH et la réponse immunitaire chez la souris.

L. THIBODEAU, M. CHAGNON, L. FLAMAND, D. ORTH, L. LACHAPELLE, C. TREMBLAY & L. MONTAGNIER.

C.R. Acad. Sci. Paris, t.309, Serie III, 741-747 (1989).

Candidate vaccines for HIV.

M. GIRARD, M.P. KIENY, J.C. GLUCKMAN, F. BARRE-SINOUSI, L. MONTAGNIER & P. FULTZ.

In : Butterworths, "*Vaccine*" (A. Mehen & R.E. Spier, eds), 1989, 227-237.

AIDS vaccines : concepts and first trials.

P. SONIGO, L. MONTAGNIER, P. TIOLLAIS & M. GIRARD.

Immunodeficiency Reviews, 1, 349-366 (1989).

Virological and immunological factors of AIDS pathogenesis.

L. MONTAGNIER, D. GUETARD, V. RAME, R. OLIVIER & M. ADAMS.

Quatrième Colloque des Cent Gardes, 1989.

Protease activation during HIV infection in a CD4-positive cell line.

G. PIEDIMONTE, P.G. PETRONINI, D. GUETARD, V. FAVIER, A.F. BORGHETTI & L. MONTAGNIER.

AIDS Research and Human Retroviruses, 6, N°2, 251-259 (1990).

Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells.

M. LEMAITRE, D. GUETARD, Y. HENIN, L. MONTAGNIER & A. ZERIAL.

Res. Virol., 141, 5-16 (1990).

HIV replication in the central nervous system of AIDS patients.

R. VAZEUX, M.C. CUMONT & L. MONTAGNIER.

In : "*Modern Pathology of AIDS and other retroviral Infections*", (Racz P., Haase AT, Gluckman JC, eds.), Basel, Karger, 1990, pp. 69-81.

Immunodeficiency : Editorial overview.

J.C. GLUCKMAN and L. MONTAGNIER.

Current opinion in Immunology, 2, 397-398 (1990).

A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity.

O. SCHWARTZ, J.L. VIRELIZIER, L. MONTAGNIER & U. HAZAN.

Gene, 88, 197-205 (1990).

Severe encephalitis resulting from coinfections with HIV and JC Virus.

R. VAZEUX, M.C. CUMONT, P.M. GIRARD, X. NASSIF, P. TROTOT, C. MARCHE, L. MATTHIESSEN, C. VEDRENNE, J. MIKOL, D. HENIN, C. KATLAMA, F. BOLGERT & L. MONTAGNIER.

Neurology, 40, 944-948 (1990).

Immunogenicity and antigenicity of conserved peptides from the envelope of HIV-1 expressed at the surface of recombinant bacteria.

A. CHARBIT, A. MOLLA, J. RONCO, J.M. CLEMENT, V. FAVIER, El M. BAHRAOUI, L. MONTAGNIER, A. LEGUERN & M. HOFNUNG.

AIDS, 4, 545-551 (1990).

Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection.

E. BAHRAOUI, A. BENJOUAD, J.M. SABATIER, J.P. ALLAIN, Y. LAURIAN, L. MONTAGNIER & J.C. GLUCKMAN.

Blood, 76, 257-264 (1990).

Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence.

M. McCHESNEY, F. TANNEAU, A. REGNAULT, P. SANSONETTI, L. MONTAGNIER, M.P. KIENY & Y. RIVIERE.

Eur. J. Immunol., 20, 215-220 (1990).

Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers.

M.A. REY, A.G. LAURENT, J. McCLURE, B. KRUST, L. MONTAGNIER & A.G. HOVANESSIAN.

J. of Virol., 64, N°2, 922-926 (1990).

Production of a non-functional nef protein in human immunodeficiency virus type 1-infected CEM cells.

A.G. LAURENT, A.G. HOVANESSIAN, Y. RIVIERE, B. KRUST, A. REGNAULT, L. MONTAGNIER, A. FINDELI, M.P. KIENY & B. GUY.

J. of Gen. Virol., 71, 2273-2281 (1990).

Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1 : evidence for antibody-dependent cellular cytotoxicity *in vivo*.

F. TANNEAU, M. McCHESNEY, O. LOPEZ, P. SANSONETTI, L. MONTAGNIER & Y. RIVIERE.

The Journal of Infectious Diseases, 162, 837-843 (1990).

A study of seroprevalence of HIV-1 and HIV-2 in six provinces of people's Republic of Angola : clues to the spread of HIV infection.

M.O. SANTOS-FERREIRA, T. COHEN, M.H. LOURENCO, M.J. MATOS ALMEIDA, S. CHAMARET & L. MONTAGNIER.

J. of Acquired Immune Deficiency Syndromes, 3, 780-786 (1990).

Export and one-step purification from Escherichia coli of a MalE-CD4 hybrid protein that neutralizes HIV *in vitro*.

S. SZMELCMAN, J.M. CLEMENT, M. JEHANNO, O. SCHWARTZ, L. MONTAGNIER & M. HOFNUNG.

J. of Acquired Immune Deficiency Syndromes, 3, 859-872 (1990).

Inhibition de l'infectiosité de souches prototypes du VIH par des anticorps dirigés contre une séquence peptidique de mycoplasme.

L. MONTAGNIER, D. BERNEMAN, D. GUETARD, A. BLANCHARD, S. CHAMARET, V. RAME, J. VAN RIETSCHOTEN, K. MABROUK & E. BAHRAOUI.

C. R. Acad. Sci. Paris, t. 311, Série III, 425-430 (1990).

A possible role of mycoplasmas as co-factors in AIDS.

L. MONTAGNIER, A. BLANCHARD, D. GUETARD, D. BERNEMAN, M. LEMAITRE, A.M. DI RIENZO, S. CHAMARET, Y. HENIN, E. BAHRAOUI, C. DAUGUET, C. AXLER, M. KIRSTETTER, R. ROUE, G. PIALOUX & B. DUPONT.

Cinquième Colloque des Cent Gardes, 1990.

Mise en évidence d'un processus d'engagement vers la mort cellulaire par apoptose dans les lymphocytes de patients infectés par le VIH.

M.L. GOUGEON, R. OLIVIER, S. GARCIA, D. GUETARD, T. DRAGIC, C. DAUGUET & L. MONTAGNIER.

C. R. Acad. Sci. Paris, t. 312, Série III, 529-537 (1991).

LAV revisited : origins of the early HIV-1 isolates from Institut Pasteur.

S. WAIN-HOBSON, J.P. VARTANIAN, M. HENRY, N. CHENCINER, R. CHEYNIER, S. DELASSUS, L. PEDROZA MARTINS, M. SALA, M.T. NUGEYRE, D. GUETARD, D. KLATZMANN, J.C. GLUCKMAN, W. ROZENBAUM, F. BARRE-SINOSSI & L. MONTAGNIER.

Science, 252, 961-965 (1991).

Early SIV encephalopathy.

B. HURTREL, L. CHAKRABARTI, M. HURTREL, M.A. MAIRE, D. DORMONT & L. MONTAGNIER.

J. Med. Primatol., 20, 159-166 (1991).

Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1_{LAI}, HIV-1_{MAL}, and HIV-1_{ELI}.

K. PEDEN, M. EMERMAN & L. MONTAGNIER.

Virology, 185, 661-672 (1991).

Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV-1 envelope glycoprotein.

B. CLERGET-RASLAIN, A. BENJOUAD, J. VAN RIETSCHOTEN, L. MONTAGNIER, H. ROCHAT & E. BAHRAOUI.

Res. Virol., 142, 423-438 (1991).

The cytopathic effect of HIV is associated with Apoptosis.

A.G. LAURENT, B. KRUST, S. MULLER, Y. RIVIERE, M.A. REY-CUILLE, J.M. BECHET, L. MONTAGNIER & A.G. HOVANESSIAN.

Virology, 185, 829-839 (1991).

Detection of HHV-6 by the polymerase chain reaction.

H. COLLANDRE, J.T. AUBIN, H. AGUT, J.M. BECHET & L. MONTAGNIER.

J. of Virol. Meth., 31, 171-180 (1991).

Early viral replication in the brain of SIV-infected rhesus monkeys.

L. CHAKRABARTI, M. HURTREL, M.A. MAIRE, R. VAZEUX, D. DORMONT, L. MONTAGNIER & B. HURTREL.

Am. J. of Path., 139, N°6, 1273-1280 (1991).

New insights on the mechanisms of CD4+ lymphocytes depletion in AIDS.

L. MONTAGNIER, M.L. GOUGEON, R. TSCHOPP, D. GUETARD, H. LECOEUR, V. RAME, S. GARCIA, O. LOPEZ & R. OLIVIER.

Sixième Colloque des Cent Gardes, 1991.

SIDA et infections à VIH : l'hypothèse de co-facteurs transmissibles.

G. PIALOUX, L. MONTAGNIER.

Cahiers Santé 1, 47-51 (1991).

Human microglial cells : Characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection.

S. PEUDENIER, C. HERY, L. MONTAGNIER & M. TARDIEU.

Ann. Neurol. 29, 152-161 (1991).

Factors and mechanisms of AIDS pathogenesis.

L. MONTAGNIER, M.L. GOUGEON, R. OLIVIER, S. GARCIA, C. DAUGUET, M. ADAMS, J.M. BECHET, D. GUETARD, A. LAURENT, A. HOVANESSIAN, M. KIRSTETTER, R. ROUE, G. PIALOUX & B. DUPONT.

In : *"Science Challenging AIDS"* (Rossi G.B., Beth-Giraldo E., Chieco-Bianchi L., Dianzani F., Giraldo G., Verani P., eds.), Basel, Karger, 1992, pp. 51-70.

Antiviral action of polyadenylic-polyuridilic acid against HIV in cell cultures.

A.G. LAURENT-CRAWFORD, B. KRUST, E. DESCHAMPS DE PAILLETTE, L. MONTAGNIER & A.G. HOVANESSIAN.

AIDS Research & Human Retroviruses, 8, N°2, 285-290 (1992).

Genetic differences accounting for evolution and pathogenicity of simian immunodeficiency virus from a sooty mangabey monkey after cross-species transmission to a pig-tailed macaque.

V. COURGNAUD, F. LAURE, P.N. FULTZ, L. MONTAGNIER, C. BRECHÔT & P. SONIGO.

J. of Virol. 66, N°1, 414-419 (1992).

Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.

A. BENJOUAD, J.C. GLUCKMAN, H. ROCHAT, L. MONTAGNIER & E. BAHRAOUI.

J. of Virol. 66, N°4, 2473-2483 (1992).

Comparison of early and late feline immunodeficiency virus encephalopathies.

M. HURTREL, J.P. GANIERE, J.F. GUELF, L. CHAKRABARTI, M.A. MAIRE, F. GRAY, L. MONTAGNIER & B. HURTREL.

AIDS 6, 399-406 (1992).

Role of Mycoplasma infection in the cytopathic effect induced by human immunodeficiency virus type 1 in infected cell lines.

M. LEMAITRE, Y. HENIN, F. DESTOUESSE, C. FERRIEUX, L. MONTAGNIER & A. BLANCHARD.

Infection and Immunity 60, N°3, 742-748 (1992).

HIV-1 infected monocytic cells can destroy human neural cells after cell-to-cell adhesion.

M. TARDIEU, C. HERY, S. PEUDENIER, O. BOESPFLUG & L. MONTAGNIER.

Annals of Neurology 32, 11-17 (1992).

New concepts in the mechanisms of CD4+ lymphocytes depletion in AIDS and the influence of opportunistic infections.

M.L. GOUGEON & L. MONTAGNIER.

In : "Mycobacteria and AIDS : Epidemiological and genetic markers, virulence factors and interactions with the immune system". 8th Forum in Microbiology.

Res. Microbiol. 143, 362-368 (1992).

Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans.

E. BAHRAOUI, A. BENJOUAD, D. GUETARD, H. KOLBE, J.C. GLUCKMAN & L. MONTAGNIER.

AIDS Research and Human Retroviruses 8, N°5, 565-573 (1992).

Functional mapping of the *rev*-responsive element of human immunodeficiency virus type 2 (HIV-2) : influence of HIV-2 envelope-encoding sequences on HIV-1 gp120 expression in the presence or absence of Rev.

S. PAULOUS, M. EMERMAN, R. KELLER, L. MONTAGNIER & A. CORDONNIER.

J. of Gen. Virol. 73, 1773-1780 (1992).

Apoptosis as a mechanism of cell death in peripheral lymphocytes from HIV-1-infected individuals.

M.L. GOUGEON, S. GARCIA, D. GUETARD, R. OLIVIER, C. DAUGUET & L. MONTAGNIER.

In : "Immunodeficiency in HIV infection and AIDS" (Janossy G., Autran B., Miedema F. (eds), EC/FERS/MRC Workshop on Immunodeficiency in HIV-1 infections, Windsor, Surrey, 1991. Basel, Karger, pp. 115-126 (1992).

Characterization of the cytotoxic immune responses to HIV-1.

F. BUSEYNE, M. McCHESNEY, F. TANNEAU, L. MONTAGNIER & Y. RIVIERE.

In : "Cytotoxic T cells in HIV and other retroviral infections ", Basel Karger, pp. 81-85 (1992).

Autoantibodies typical of non-organ-specific autoimmune diseases in HIV-seropositive patients.

S. MULLER, P. RICHALET, A. LAURENT-CRAWFORD, S. BARAKAT, Y. RIVIERE, F. PORROT, S. CHAMARET, J.P. BRIAND, L. MONTAGNIER & A. HOVANESSIAN.
AIDS 6, 933-942 (1992).

Modulation of cell growth and host protein synthesis during HIV infection *in vitro*.
A.M. DI RIENZO, P.G. PETRONINI, D. GUETARD, R. FAVILLA, A.F. BORGHETTI, L. MONTAGNIER & G. PIEDIMONTE.
J. of Acq. Imm. Def. Synd. 5, 921-929 (1992).

Detection of human immunodeficiency virus type 2 in brain tissue.
D.E. DWYER, S. MATHERON, S. BAKCHINE, J.M. BECHET, L. MONTAGNIER & R. VAZEUX.
J. of Infect. Dis. 166, 888-891 (1992).

Etude de l'inactivation *in vitro* par le Solubacter du virus de l'immunodéficience humaine mis en présence ou non de liquide de lavage vaginal.
L. MONTAGNIER
Médecine d'Afrique Noire 39 (7) (1992).

Amplification factors of HIV in AIDS patients.
L. MONTAGNIER, M.L. GOUGEON, D. GUETARD, V. RAME, C. AXLER & C. DAUGUET.
In : Retroviruses of human AIDS and related animal diseases : proceedings of the **Septième Colloque des Cent Gardes**, 1992, p. 83-86 (M. Girard and L. Valette, eds.), Fondation Mérieux, Lyon.

Isolation of atypical HIV-1-related retrovirus from AIDS patient.
H. AGUT, D.CANDOTTI, B. RABANEL, J.M. HURAUX, G. REMY, D. INGRAND, T. TABARY, C. CHIPPAUX, S. CHAMARET, D. GUETARD, C. DAUGUET & L. MONTAGNIER.
The Lancet, 712, 26 mars 1992.

Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women.
Y. HENIN, L. MANDELBROT, R. HENRION, R. PRADINAUD, J.P. COULAUD & L. MONTAGNIER.
J. of Acq. Imm. Def. Synd. 6, 72-75 (1993).

Development of a selective and sensitive polymerase chain reaction assay for the detection of *Mycoplasma pirum*.
O. GRAU, R. KOVACIC, R. GRIFFAIS & L. MONTAGNIER.
FEMS Microbiology Letters 106, 327-334 (1993).

New concepts in AIDS pathogenesis.
M.L. GOUGEON, V. COLIZZI, A. DALGLEISH & L. MONTAGNIER.
AIDS Research and Human Retroviruses 9, 267-269 (1993).

Direct and indirect mechanisms mediating apoptosis during HIV infection : contribution to *in vivo* CD4 T cell depletion.

M.L. GOUGEON, A.G. LAURENT-CRAWFORD, A. HOVANESSIAN & L. MONTAGNIER.
Seminars in Immunology 5, 306-313 (1993).

Characterization of a nuclear retention sequence within the 3' region of the HIV-2 envelope gene.
R. KELLER, L. MONTAGNIER & A. CORDONNIER.
Virology 192, 33-37 (1993).

Target cells during early SIV encephalopathy.
B. HURTREL, L. CHAKRABARTI, M. HURTREL & L. MONTAGNIER.
Res. Virol. 144, 41-46 (1993).

Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
A. BENJOUAD, J.C. GLUCKMAN, L. MONTAGNIER & E. BAHRAOUI.
J. of Virol. 67, N°3, 1693-1697 (1993).

Phylogenetic analysis of *Mycoplasma penetrans*, isolated from HIV-infected patients.
N. BEHBAHANI, A. BLANCHARD, G.H. CASSELL & L. MONTAGNIER.
FEMS Microbiology Letters 109, 63-66 (1993).

N-linked oligosaccharides of simian immunodeficiency virus envelope glycoproteins are dispensable for the interaction with the CD4 receptor.
A. BENJOUAD, T. BABAS, L. MONTAGNIER & E. BAHRAOUI.
Biochem. and Biophys. Res. Commun. 190, N°2, 311-319 (1993).

Early central nervous system changes in human immunodeficiency virus (HIV)-infection.
F. GRAY, M. HURTREL & B. HURTREL.
Neuropathology and Applied Neurobiology 19, 3-9 (1993).

Mycoplasma as cofactors in AIDS.
L. MONTAGNIER
In : "New Concepts in AIDS Pathogenesis", L. Montagnier & M.L. Gougeon, eds., Marcel Decker, Inc., pp. 115-125, 1993.

Programmed cell death during HIV-infection and correlation with AIDS pathogenesis.
M.L. GOUGEON, S. GARCIA, J. HEENEY & L. MONTAGNIER.
In : "New Concepts in AIDS pathogenesis", L. Montagnier and M.L. Gougeon eds., Marcel Dekker, pp. 153-169.

Apoptosis in AIDS.
M.L. GOUGEON & L. MONTAGNIER.
Science 260, 1269-1270 (1993).

Programmed cell-death in AIDS-related HIV and SIV infections.
M.L. GOUGEON, S. GARCIA, J. HEENEY, R. TSCHOPP, H. LECOEUR, D. GUETARD, V. RAME, C. DAUGUET & L. MONTAGNIER.

AIDS Res. and Hum. Retrov. 9, 553-563 (1993).

Antigenic and genetic differentiation of the two putative types of human herpes virus 6.

J.T. AUBIN, H. AGUT, H. COLLANDRE, K. YAMANISHI, B. CHANDRAN, L. MONTAGNIER & J.M. HURAUX.

J. of Virol. Methods 41, 223-234 (1993).

Human Herpesvirus 6 strain groups : a nomenclature.

D. ABLASHI, H. AGUT, Z. BERNEMAN, G. CAMPADELLI-FIUME, D. CARRIGAN, L. CECCERINI-NELLI, B. CHANDRAN, S. CHOU, H. COLLANDRE, R. CONE, T. DAMBAUGH, S. DEWHURST, D. DILUCA, L. FOA-TOMASI, B. FLECKENSTEIN, N. FRENKEL, R. GALLO, U. GOMPELS, C. HALL, M. JONES, G. LAWRENCE, M. MARTIN, L. MONTAGNIER, F. NEIPEL, J. NICHOLAS, P. PELLETT, A. RFAZZAQUE, G. TORRELLI, B. THOMSON, S. SALAHUDDIN, L. WYATT, K. YAMANISHI.

Archives of Virology, mars 1993.

Identification of *Mycoplasma pirum* genes involved in the salvage pathways for nucleosides.

T.N. THAM, S. FERRIS, R. KOVACIC, L. MONTAGNIER & A. BLANCHARD.

J. of Bact. 175, N°16, 5281-5285 (1993).

Is a dominant superantigen involved in AIDS pathogenesis ?

M.L. GOUGEON, G. DADAGLIO, S. GARCIA, H. MÜLLER-ALOUF, R. ROUE & L. MONTAGNIER.

The Lancet 342, 3 Juillet 1993.

Mycoplasmas as cofactors in infection due to the Human Immunodeficiency Virus.

L. MONTAGNIER & A. BLANCHARD.

Clin. Infect. Dis. 17, 309-315 (1993).

Late seroconversion in three multitransfused young haemophiliacs confirmed by HIV PCR analysis.

M.L.J. MONCANY, A. BERTHIER, P. MARKOULATOS & L. MONTAGNIER.

J. of Vir. Dis. 1, N°3, 14-23 (1993).

The resistance of HIV-infected chimpanzees to progression to AIDS correlates with absence of HIV-related T-cell dysfunction.

J. HEENEY, R. JONKER, W. KOORNSTRA, R. DUBBES, H. NIPHUIS, A.M. DI RIENZO, M.L. GOUGEON & L. MONTAGNIER.

J. Med. Primatol., 22, 194-200 (1993).

Amino acid changes in the fourth conserved region of human immunodeficiency virus type 2 strain HIV-2ROD envelope glycoprotein modulate fusion.

R. KELLER, K. PEDEN, S. PAULOUS, L. MONTAGNIER & A. CORDONNIER.

J. of Virol. 67, N°10, 6253-6258 (1993).

Spermatozoa as potential carriers of HIV.

E. DUSSAIX, D. GUETARD, C. DAUGUET, M. D'ALMEIDA, J. AUER, A. ELLRODT, L. MONTAGNIER & M. AUROUX.

Res. Virol. 144, 487-495 (1993).

Different proliferative response of human and chimpanzee lymphocytes after contact with human immunodeficiency virus type 1 gp120

A.M. DI RIENZO, G. FURLINI, R. OLIVIER, S. FERRIS, J. HEENEY & L. MONTAGNIER.
Eur. J. Immunol. 24, 34-40 (1994).

Molecular characterization of the P1-like adhesin gene from *Mycoplasma pirum*.

T.N. THAM, S. FERRIS, E. BAHRAOUI, S. CANARELLI, L. MONTAGNIER & A. BLANCHARD.
J. of Bact. 176, N°3, 781-788 (1994).

Selective anergy of V β 8+ T cells in human immunodeficiency virus-infected individuals.

G. DADAGLIO, S. GARCIA, L. MONTAGNIER & M.L. GOUGEON.
J. Exp. Med. 179, 413-424 (1994).

Prevention of early cell death in peripheral blood lymphocytes of HIV infected individuals by an anti-oxidant : N-acetyl-cysteine.

R. OLIVIER, O. LOPEZ, M. MOLLEREAU, T. DRAGIC, D. GUETARD & L. MONTAGNIER.
In : "Oxidative Stress, Cell Activation and Viral Infection (C. Pasquier et al. eds), Birkhäuser Verlag Basel, Switzerland, p. 323-332 (1994).

Apoptosis in peripheral T lymphocytes during HIV infection : influence of superantigens and correlation with AIDS pathogenesis.

M.L. GOUGEON & L. MONTAGNIER.

In : "Apoptosis II : The molecular basis of apoptosis in disease" (L.D. Tomei & F.O. Cope, eds), Cold Spring Harbor Laboratory Press, pp. 5-19 (1994).

Kinetics of primary SIV infection in lymph nodes.

L. CHAKRABARTI, M.C. CUMONT, L. MONTAGNIER & B. HURTREL.
J. Med. Primatol. 23, 117-124 (1994).

Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells.

L. CHAKRABARTI, P. ISOLA, M.C. CUMONT, M.A. CLAESSENS-MAIRE, M. HURTREL, L. MONTAGNIER & B. HURTREL.

Am. J. of Path. 144, N°6, 1226-1236 (1994).

Human immunodeficiency viruses.

L. MONTAGNIER & F. CLAVEL.

In : "Encyclopedia of Virology", Academic Press Ltd., 674-681, 1994.

Inhibition of HIV type 1 reverse transcriptase assay by nucleases produced by contaminating mycoplasmas.

C. QUILLET, O. GRAU, F. CLAVEL, L. MONTAGNIER & A. BLANCHARD.
AIDS Res. & Hum. Ret. 10, 1251-1257 (1994).

HIV-2 EHO isolate has a divergent envelope gene and induces single cell killing by apoptosis.

M.A. REY-CUILLE, J. GALABRU, A. LAURENT-CRAWFORD, B. KRUST, L. MONTAGNIER & A.G. HOVANESSIAN.

Virology 202, 471-476 (1994).

Variable course of primary simian immunodeficiency virus infection in lymph nodes : relation to disease progression.

L. CHAKRABARTI, M.C. CUMONT, L. MONTAGNIER & B. HURTREL.

J. of Virol. 68, N°10, 6634-6642 (1994).

AIDS-associated mycoplasmas.

A. BLANCHARD & L. MONTAGNIER.

Ann. Rev. Microbiol. 48, 687-712 (1994).

Identification of an adhesin-like gene of *Mycoplasma pirum* isolated from AIDS patients.

T.N. THAM, S. FERRIS, E. BAHRAOUI, S. CANARELLI, L. MONTAGNIER & A. BLANCHARD.

Ann. N.Y. Acad. Sci. 730, 279-282 (1994).

Early events in lymph nodes during infection with SIV and FIV.

B. HURTREL, L. CHAKRABARTI, M. HURTREL, J.M. BACH, J.P. GANIERE & L. MONTAGNIER.

Res. Virol. 145, 221-227 (1994).

Isolation and envelope sequence of a highly divergent HIV-1 isolate : Definition of a new HIV-1 group.

P. CHARNEAU, A.M. BORMAN, C. QUILLET, D. GUETARD, S. CHAMARET, J. COHEN, G. REMY, L. MONTAGNIER & F. CLAVEL.

Virology 205, 247-253 (1994).

Specificity of anti-peptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.

T. BABAS, S. BENICHO, D. GUETARD, L. MONTAGNIER & E. BAHRAOUI.

Molecular Immunol. 31, N°5, 361-369 (1994).

Effect of calcium ions on proteolytic processing of HIV-1 gp160 precursor and on cell fusion.

M. MOULARD, L. MONTAGNIER & E. BAHRAOUI.

FEBS Lett. 338, 281-284 (1994).

Kex2p : a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor.

M. MOULARD, T. ACHSTETTER, M.P. KIENY, L. MONTAGNIER & E. BAHRAOUI.

Eur. J. Biochem. 225, 565-572 (1994).

Factors of AIDS pathogenesis.

L. MONTAGNIER

Neuvième Colloque des Cent Gardes 1994, p. 213-216.

Apoptosis as a consequence of the general state of immune activation in HIV-infection. Influence on Bcl-2 expression.

M.L. GOUGEON, H. LECOEUR, F. BOUDET, A. DULIOUST, M.G. ENOUF, M. CROUVOISIER & L. MONTAGNIER.

In : "*Retroviruses of Human AIDS and related animal diseases*" (M. Girard and L. Valette, eds.), Fondation M. Mérieux, 9è Colloque des Cent Gardes, p. 37-41.

Development of PCR-based assays for the detection of two human mollicute species, *Mycoplasma penetrans* and *M. hominis*.

O. GRAU, R. KOVACIC, R. GRIFFAIS, V. LAUNAY & L. MONTAGNIER.

Molecular and Cellular Probes 8, 139-148 (1994).

Kaposi's sarcoma and new herpesvirus

H. COLLANDRE, S. FERRIS, O. GRAU, L. MONTAGNIER & A. BLANCHARD.

The Lancet 345, N°8956, p. 1043 (1995).

Characterization of a major *Mycoplasma penetrans* lipoprotein and of its gene.

S. FERRIS, H.L. WATSON, O. NEYROLLES, L. MONTAGNIER & A. BLANCHARD.

FEMS Microbiol. Lett. 130, 313-320 (1995).

Association of *Mycoplasma penetrans* with human immunodeficiency virus infection.

O. GRAU, B. SLIZEWICZ, P. TUPPIN, V. LAUNAY, E. BOURGEOIS, N. SAGOT, M. MOYNIER, A. LAFEUILLADE, H. BACHELEZ, J.P. CLAUVEL, A. BLANCHARD, E. BAHRAOUI & L. MONTAGNIER.

J. of Infect. Dis. 172, 672-681 (1995).

Limited viral spread and rapid immune response in lymph nodes of macaques inoculated with attenuated simian immunodeficiency virus.

L. CHAKRABARTI, V. BAPTISTE, E. KHATISSIAN, M.C. CUMONT, A.M. AUBERTIN, L. MONTAGNIER & B. HURTREL.

Virology 213, 535-548 (1995).

Rapport sur la transmission hétérosexuelle du VIH en France.

L. MONTAGNIER

Bull. Acad. Natle. Méd. 179, n°6, 1209-1224 (1995).

Nef vaccination against HIV disease.

L. MONTAGNIER

The Lancet 346, N° 8983, p.1170 (1995).

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

Y. RIVIERE, M.B. McCHESNEY, F. PORROT, F. TANNEAU-SALVADORI, P. SANSONETTI, O. LOPEZ, G. PIALOUX, V. FEUILLIE, M. MOLLEREAU, S. CHAMARET, F. TEKAIA & L. MONTAGNIER

AIDS Research and Human Retroviruses, 11, N°8, 903-907 (1995).

In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Y. SASAKI, A. BLANCHARD, H.L. WATSON, S. GARCIA, A. DULIOUST, L. MONTAGNIER & M.L. GOUGEON.

Infect. Immun., 63, 4277-4283 (1995).

Specificity and neutralizing capacity of three monoclonal antibodies produced against the envelope glycoprotein of simian immunodeficiency virus isolate 251.

T. BABAS, B. BELHADJ-JRAD, R. LE GRAND, D. DORMONT, L. MONTAGNIER & E. BAHRAOUI.

Virology, 211, 339-344 (1995).

Testing and quantitation of HIV infection.

L. MONTAGNIER

In : "AIDS Research at EC level (Series : Biomedical and Health Research, 6, 1995, p. 240-250).

Possible value of nef vaccination against HIV disease.

L. MONTAGNIER

Xème Colloque des Cent Gardes, 1995.

Atypical HIV serological profile of novel HIV-1 variant distinct from subtype O.

J. COHEN, D. GUETARD, F. PHILBERT, S. CHAMARET, T. TABARY, R. DELEYS & L. MONTAGNIER.

The Lancet, 345, 856-857 (1995).

Inhibition of *in vitro* HIV infection by trinitrophenyl-protein conjugates.

P. MATSIOTA-BERNARD, D. GUETARD, V. RAME, L. MONTAGNIER and S. AVRAMEAS.

Res. Immunol., 146, 109-117 (1995).

Low susceptibility of resident microglia to simian immunodeficiency virus replication during the early stages of infection.

D. BOCHE, F. GRAY, L. CHAKRABARTI, M. HURTREL, L. MONTAGNIER B. HURTREL.

Neuropath. & Applied Neurobiol., 21, 535-539 (1995).

Organisation of *Ureaplasma urealyticum* urease gene cluster and expression in a suppressor strain of *Escherichia coli*.

O. NEYROLLES, S. FERRIS, N. BEHBAHANI, L. MONTAGNIER & A. BLANCHARD.

J. Bacteriol., 178, N°3, 647-655 (1996).

Environmental pathogenesis of human retroviruses.

L. MONTAGNIER

AIDS Res. & Hum. Retr., 12, N°5, 357-359 (1996).

Increased plasma thiobarbituric acid-reactive substances (TBARS) before opportunistic infection symptoms in HIV-infected individuals.

O. LOPEZ, D. BONNEFONT-ROUSSELOT, M. MOLLEREAU, R. OLIVIER, L. MONTAGNIER, J. EMERIT, M. GENTILINI & J. DELATTRE.

Clin. Chim. Acta, 247, 181-187 (1996).

Programmed cell death in peripheral lymphocytes from HIV-infected persons : Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.

M.L. GOUGEON, H. LECOEUR, A. DULIOUST, M.G. ENOUF, M. CROUVOISIER, C. GOUJARD, T. DEBORD & L. MONTAGNIER.

The J. of Immunol., 156, 3509-3520 (1996).

Search for the presence of six Mycoplasma species in peripheral blood mononuclear cells of subjects seropositive and seronegative for Human Immunodeficiency Virus.

R. KOVACIC, V. LAUNAY, P. TUPPIN, A. LAFEUILLADE, V. FEUILLIE, L. MONTAGNIER & O. GRAU.

J. Clin. Microbiol., 34 (N°7), 1808-1810 (1996).

The relationship between the interferon α response and viral burden in primary SIV infection.

E. KHATISSIAN, M.G. TOVEY, M.C. CUMONT, V. MONCEAUX, P. LEBON, L. MONTAGNIER, B. HURTREL & L. CHAKRABARTI.

AIDS Res. & Hum. Retr., 12, N°13, 1273-1278 (1996).

AIDS pathogenesis : implications for treatment and vaccines.

L. MONTAGNIER

European Journal of Pharmaceutical Sciences, 4, Suppl. S5 (1996).

Selective loss of CD4+/CD26+ T cell subset during HIV infection.

M.L. GOUGEON, H. LECOEUR, C. CALLEBAUT, E.JACOTOT, A. DULIOUST, R. ROUE, L. MONTAGNIER & A. HOVANESSIAN.

Res. Immunol., 147, 5-8 (1996).

Virus load and neuropathology in the FIV model.

D. BOCHE, M. HURTREL, F. GRAY, M.A. CLAESSENS-MAIRE, J.P. GANIERE, L. MONTAGNIER & B. HURTREL.

J. of Neurovirol., 2, 377-387 (1996).

Interferon-gamma expression in the lymph nodes of macaques during primary SIV infection. KHATISSIAN E., MONCEAUX V., CUMONT M.C., MONTAGNIER L., HURTREL B. & CHAKRABARTI L.

Cytokine, November issue, pp. 844-852 (1996).

Immune correlates of protection from HIV infection and AIDS.

J.L. HEENEY, C. BRUCK, J. GOUDSMIT, L. MONTAGNIER, A. SCHULTZ, D. TYRRELL & S. ZOLLA-PAZNER. From "The International Workshop on Immunological correlates of protection from

HIV infection and disease, Montreux, Switzerland, May 1995.
Immunol. Today, 18, 4-8 (1997).

Human immunodeficiency virus infection and AIDS in a person with negative serology.
L. MONTAGNIER, C. BRENNER, S. CHAMARET, D. GUETARD, A. BLANCHARD, J. DE SAINT-MARTIN, J.D. POVEDA, G. PIALOUX & M.L. GOUGEON.
J. of Infect. Dis., 175, 955-959 (1997).

Purification and characterization of Mycoplasma penetrans Ca^{2+} / Mg^{2+} -dependent endonuclease.
M. BENDJENNAT, A. BLANCHARD, M. LOUFTI, L. MONTAGNIER & E. BAHRAOUI.
J. of Bacteriology, 179, N°7, 2210-2220 (1997).

Le SIDA, Dix ans après
L. MONTAGNIER
La Gazette Médicale, N°8, 104, 72-73, avril 1997.

Influence of microbial infections on the progression of HIV disease.
A. BLANCHARD, L. MONTAGNIER & M.L. GOUGEON.
Trends in Microbiol., 5, 326-331 (1997).

Spiralin, a mycoplasmal membrane lipoprotein, induces T-cell-independent B-cell blastogenesis and secretion of proinflammatory cytokines.
C. BRENNER, H. WROBLEWSKI, M. LE HENAFF, L. MONTAGNIER & A. BLANCHARD.
Infect. Immun., 65, N°10, 4322-4329 (1997).

Oxidative protein damage and degradation in lymphocytes from patients infected with human immunodeficiency virus.
G. PIEDIMONTE, D. GUETARD, M. MAGNANI, D. CORSI, I. PICERNO, P. SPATARO, L. KRAMER, M. MONTRONI, G. SILVESTRI, J.F. TORRES-ROCA & L. MONTAGNIER.
J. of Infect. Dis., 176, 655-664 (1997).

Apport des modèles animaux dans la compréhension de l'encéphalopathie SIDA.
D. BOCHE, F. GRAY, E. KHATISSIAN, M. HURTREL, L. MONTAGNIER & B. HURTREL.
Arch. Anat. Cytol. Path., 45, n° 2-3, 75-85 (1997).

High prevalence of antibodies to Mycoplasma penetrans in human immunodeficiency virus-seronegative and -seropositive populations in Brazzaville, Congo.
P. TUPPIN, O. DELAMARE, V. LAUNAY, M. GUEGUEN, M.C. SAMBA, L. PAMBOU, L. MONTAGNIER & O. GRAU.
Clin. & Diagn. Lab. Immunol., 4, N°6, 787-788 (1997).

Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods.
H. LECOEUR, E. LEDRU, M.C. PREVOST & M.L. GOUGEON.
J. of Immunol. Meth., 209, 111-123 (1997).

Protein degradation in lymphocytes as an indicator of oxidative stress in HIV infection.

PIEDIMONTE G., MAGNANI M., CORSI D., TORRES-ROCCA J.F., GUETARD D. & MONTAGNIER L.

In "Oxidative Stress in Cancer, AIDS and Neurodegenerative Diseases" (L. Montagnier, R. Olivier & C. Pasquier, eds.), Marcel Dekker Inc., 399-408 (1997)

Identification of two glycosylated components of *Mycoplasma penetrans* : a surface-exposed capsular polysaccharide and a glycolipid fraction.

NEYROLLES O., BRENNER C., PREVOST M.C., FONTAINE T., MONTAGNIER L. and BLANCHARD A.

Microbiology, 144, 1247-1255 (1998).

Molecular evidence for nosocomial transmission of human immunodeficiency virus from a surgeon to one of his patients.

BLANCHARD A., FERRIS S., CHAMARET S., GUETARD D. and MONTAGNIER L.

J. of Virol., 72, n°5, 4537-4540 (1998).

HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.

QUILLET C., OBERLIN E., BRAUN J., ROUSSET D., GONZALEZ-CANALI G., METAIS P., MONTAGNIER L., VIRELIZIER J.L., ARENZANASEISDEDOS F. and BERETTA A.

Lancet, 351(9095), 14-18 (1998, 3 Janvier).

A longitudinal study of seroreactivity against *Mycoplasma penetrans* in HIV-infected homosexual men : association with disease progression.

GRAU O., TUPPIN P., SLIZEWICZ B., LAUNAY V., GOUJARD C., BAHRAOUI E., DELFRAISSY J.F. and MONTAGNIER L.

AIDS Res. and Hum. Retr., 14, N°8, 661-667 (1998).

Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. CUILLE M.A., BERTHIER J.L., BOMSEL-DEMONTOV M.C., CHADUC Y., MONTAGNIER L., HOVANESSIAN A.G. and CHAKRABARTI L.

Journal of Virology, 72, n°5, 3872-3886 (1998).

Phase variations of the *Mycoplasma penetrans* main surface lipoprotein increase antigenic diversity.

NEYROLLES O., CHAMBAUD I., FERRIS S., PREVOST M.C., SASAKI T., MONTAGNIER L. and BLANCHARD A.

Infect. and Immun., 67, 1569-1578 (1999).

Viral load and neuropathology in the SIV model.

BOCHE D., KHATISSIAN E., GRAY F., FALANGA P., MONTAGNIER L. and HURTREL B.

J. Neuroviro., 5 N°3, 232-240 (1999).

Programmed cell death as a mechanism of CD4 and CD8T cell deletion in AIDS - Molecular control and effect of highly active anti-retroviral therapy.

GOUGEON M.L. and MONTAGNIER L.

Annals of the New York Academy of Sciences, 887, 199-212 (1999).

Les tentatives de mise au point d'un vaccin sous-unitaire contre le SIDA.

DAUDEL R. and MONTAGNIER L.
C.R. Acad. Sci. Paris, t.2, Série Iic, p. 471-476 (1999).

HIV-1 genome nuclear import is mediated by a central DNA flap.
ZENNOU V., PETIT C., GUETARD D., NEHRBASS U., MONTAGNIER L. and CHARNEAU P.
Cell, *101*, 173-185 (2000).

A history of HIV discovery.
MONTAGNIER L.
Science, *298*, 1727-1728, (29 Nov. 2002)

Prospects for the future.
GALLO R.C. and MONTAGNIER L.
Science, *298*, 1730-1731, (29 Nov. 2002)

The discovery of HIV as the cause of AIDS.
GALLO R.C. and MONTAGNIER L.
The New Engl. J. of Med., *349*, 2283-2285 (11 Dec. 2003)

Aids, hepatitis and hemophilia.
MONTAGNIER L.
J. Thrombosis and haemostatis, *2*, 514-521, (2004)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.